efegatran has been researched along with Coronary Thrombosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gesellchen, PD; Growe, VG; Jackson, CV; Shuman, RT; Wilson, HC | 1 |
| Bailey, BD; Crowe, VG; Jackson, CV; Shetler, TJ | 1 |
| Coffman, WJ; Crowe, VG; Frank, JD; Jackson, CV; Jakubowski, JA; Smith, GF; Utterback, BG; Wilson, HC | 1 |
3 other study(ies) available for efegatran and Coronary Thrombosis
| Article | Year |
|---|---|
Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis: a comparison with heparin in a canine model of coronary artery thrombosis.
Topics: Animals; Antithrombins; Bleeding Time; Coronary Thrombosis; Disease Models, Animal; Dogs; Female; Hemodynamics; Heparin; Oligopeptides; Tissue Plasminogen Activator | 1993 |
Antithrombotic assessment of the effects of combination therapy with the anticoagulants efegatran and heparin and the glycoprotein IIb-IIIa platelet receptor antagonist 7E3 in a canine model of coronary artery thrombosis.
Topics: Abciximab; Animals; Antibodies, Monoclonal; Bleeding Time; Blood Pressure; Coronary Thrombosis; Dogs; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heart Rate; Heparin; Immunoglobulin Fab Fragments; Male; Oligopeptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex | 1996 |
Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis.
Topics: Animals; Anticoagulants; Blood Coagulation; Coronary Thrombosis; Dogs; Heparin; Infusions, Intravenous; Models, Cardiovascular; Oligopeptides; Partial Thromboplastin Time; Platelet Aggregation; Platelet Aggregation Inhibitors; Prothrombin Time | 1992 |